Tolvaptan

BNF:
6.3.2
Status:
Red
Decision Date:
September 2015
 

Comments

RED1: NICE TA358: for treating autosomal dominant polycystic kidney disease. (Decision date -  November 2015)

 

CCG commissioned drug for autosomal dominant polycystic kidney disease

NHS England commissioned drug for hyponatraemia .

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app